Skip to main content
Premium Trial:

Request an Annual Quote

John Oyler, BTX

Premium

People in the News

John Oyler has left RNAi startup Galenea as CEO, RNAi News has learned.

According to Pamela Esposito, who is in charge of business development and strategic planning at the company, Oyler left about a month ago to pursue another entrepreneurial opportunity.

She said that the company is "grateful to John for the two years he gave to Galenea."

She noted that Galenea is actively searching for a new CEO.

 

Products & Services

BTX has introduced the BTX high-throughput electroporation system for delivering siRNA and DNA expression vectors into mammalian cells.

According to the company, the system consists of a 96-well electroporation plate along with a 96-well plate handler. The system's interface allows for variable voltage and pulse length, and processes 96 samples in less than 1 minute, the company added.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.